US biopharmaceutical company
US biopharmaceutical company
Phase 3 data for Merck & Co. and Moderna’s personalized mRNA cancer vaccine intismeran autogene were presented at ESMO’s Presidential Symposium in Madrid, days after a pre-conference data leak.
The FDA has approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in patients aged 12 and older, making it the third approved FOP therapy and the second in five weeks.
You must be logged in to post a comment.